=> fil reg

FILE 'REGISTRY' ENTERED AT 16:22:01 ON 20 MAR 1998

STRUCTURE FILE UPDATES: 16 MAR 98 HIGHEST RN 202643-83-2
DICTIONARY FILE UPDATES: 19 MAR 98 HIGHEST RN 202643-83-2

TSCA INFORMATION NOW CURRENT THROUGH JUNE 1997

Please note that search-term pricing does apply when conducting SmartSELECT searches.

=> d ide can l17 tot

L17 ANSWER 1 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 103667-50-1 REGISTRY
CN **2-Thiopheneacetic acid, 5-benzoyl-.alpha.-methyl-, (S)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN (-)-Tiaprofenic acid
CN (S)-Tiaprofenic acid
CN RU 40519
FS STEREOSEARCH
MF **C14 H12 O3 S**
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, DRUGPAT, IPA, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



37 REFERENCES IN FILE CA (1967 TO DATE)
37 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:351317

REFERENCE 2: 127:55978

REFERENCE 3: 127:39933

REFERENCE 4: 127:9170

REFERENCE 5: 126:311911

REFERENCE 6: 126:308861

REFERENCE 7: 126:217

REFERENCE 8: 125:237558

REFERENCE 9: 124:331593

REFERENCE 10: 124:270111

L17 ANSWER 2 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 103667-49-8 REGISTRY
CN **2-Thiopheneacetic acid, 5-benzoyl-.alpha.-methyl-, (R)-**
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Tiaprofenic acid
CN (R)-Tiaprofenic acid
CN RU 40518
FS STEREOSEARCH
MF **C14 H12 O3 S**
CI COM
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, DRUGPAT, IPA, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



32 REFERENCES IN FILE CA (1967 TO DATE)
32 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:351317

REFERENCE 2: 127:55978

REFERENCE 3: 127:39933

REFERENCE 4: 127:9170

REFERENCE 5: 126:311911

REFERENCE 6: 126:308861

REFERENCE 7: 126:217

REFERENCE 8: 125:317341

REFERENCE 9: 125:237558

REFERENCE 10: 124:331593

L17 ANSWER 3 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 56105-81-8 REGISTRY
CN **Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, (R)- (9CI)**
(CA INDEX NAME)
OTHER NAMES:
CN **(-)-2-(3-Benzoylphenyl)propionic acid**
CN **(-)-3-Benzoyl-.alpha.-methylbenzeneacetic acid**
CN (-)-Ketoprofen
CN **(2R)-2-(3-Benzoylphenyl)propionic acid**
CN **(R)-2-(3-Benzoylphenyl)propionic acid**
CN **(R)-3-Benzoyl-.alpha.-methylphenylacetic acid**
CN (R)-Ketoprofen
CN R-(-)-Ketoprofen
FS STEREOSEARCH
MF **C16 H14 O3**
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CEN, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DRUGNL, DRUGPAT, DRUGUPDATES, IPA, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



180 REFERENCES IN FILE CA (1967 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
181 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:136065

REFERENCE 2: 128:135908

REFERENCE 3: 128:119736

REFERENCE 4: 128:102282

REFERENCE 5: 128:97725

REFERENCE 6: 128:85960

REFERENCE 7: 128:53252

REFERENCE 8: 127:362485

REFERENCE 9: 127:351317

REFERENCE 10: 127:302703

L17 ANSWER 4 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 51146-57-7 REGISTRY
CN **Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, (R)-**
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-.alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid
CN (-)-Ibuprofen
CN (-)-Ibuprophen
CN (R)-(-)-Ibuprofen
CN (R)-2-(4-Isobutylphenyl)propanoic acid
CN (R)-Ibuprofen
CN l-Ibuprofen
CN R-(-)-p-Isobutylhydratropic acid
FS STEREOSEARCH
MF **C13 H18 O2**
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CIN, CJACS, CSCHEM, IPA, PNI, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



369 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
372 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:132523

REFERENCE 2: 128:119736

REFERENCE 3: 128:106477

REFERENCE 4: 128:102282

REFERENCE 5: 128:97725

REFERENCE 6: 128:93278

REFERENCE 7: 128:93217

REFERENCE 8: 128:57078

REFERENCE 9: 128:29857

REFERENCE 10: 127:355136

L17 ANSWER 5 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 51146-56-6 REGISTRY
CN **Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, (S)-(9CI)** (CA INDEX NAME)
OTHER NAMES:
CN (+)-(S)-p-Isobutylhydratropic acid
CN (+)-.alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid
CN (+)-Ibuprofen
CN (+)-Ibuprophen
CN (+)-S-Ibuprofen
CN (S)-(+)-4-Isobutyl-.alpha.-methylphenylacetic acid
CN (S)-(+)-Ibuprofen
CN (S)-2-(4-Isobutylphenyl)propanoic acid
CN (S)-2-(4-Isobutylphenyl)propionic acid
CN (S)-2-(p-Isobutylphenyl)propionic acid
CN (S)-Ibuprofen
CN d-Ibuprofen
CN Dexibuprofen
FS STEREOSEARCH
MF **C13 H18 O2**
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CBNB, CIN, CJACS, CSCHEM, EMBASE, IPA, MEDLINE, PHAR, PNI, PROMT, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry. Rotation (+).



513 REFERENCES IN FILE CA (1967 TO DATE)
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
517 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:132523

REFERENCE 2: 128:132449

REFERENCE 3: 128:119736

REFERENCE 4: 128:106477

REFERENCE 5: 128:102282

REFERENCE 6: 128:97725

REFERENCE 7: 128:93278

REFERENCE 8: 128:93217

REFERENCE 9: 128:57078

REFERENCE 10: 128:48044

L17 ANSWER 6 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN **33005-95-7** REGISTRY
CN **2-Thiopheneacetic acid, 5-benzoyl-.alpha.-methyl- (8CI, 9CI)**
(CA INDEX NAME)
OTHER NAMES:
CN (.+-.)-Tiaprofenic acid
CN (RS)-Tiaprofenic acid
CN FC 3001
CN RU 15060
CN Surgam
CN Tiaprofen
CN Tiaprofenic acid
FS 3D CONCORD
DR 39984-70-8
MF **C14 H12 O3 S**
CI COM
LC STN Files: ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CHEMLIST, CBNB, CIN, CSCHEM, DDFU, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PIRA, PHAR, PNI, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



277 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
277 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:119657

REFERENCE 2: 128:101012

REFERENCE 3: 128:99314

REFERENCE 4: 128:93088

REFERENCE 5: 128:93087

REFERENCE 6: 128:58349

REFERENCE 7: 128:43397

REFERENCE 8: 128:16464

REFERENCE 9: 128:10141

REFERENCE 10: 128:7402

L17 ANSWER 7 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 23981-80-8 REGISTRY
CN **2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl- (8CI, 9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(.+-.)-2-(6-Methoxy-2-naphthalenyl)propionic acid**
CN **(.+-.)-2-(6-Methoxy-2-naphthyl)propionic acid**
CN **(.+-.)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid**
CN (.+-.)-Naproxen
CN (RS)-Naproxen
CN **.alpha.-(6-Methoxy-2-naphthyl)propionic acid**
CN **2-(6-Methoxy-2-naphthyl)propanoic acid**
CN **2-(6-Methoxy-2-naphthyl)propionic acid**
CN **6-Methoxy-2-naphthyl-.alpha.-methylacetic acid**
CN dj-Naproxen
CN **dl-2-(6-Methoxy-2-naphthyl)propionic acid**
CN dl-Naproxen
CN Racemic naproxen
FS 3D CONCORD
DR 26159-31-9
MF **C14 H14 O3**
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, CHEMLIST, CJACS, CSCHEM, DRUGPAT, IFICDB, IFIPAT, IFIUDB, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



203 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
204 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:119736

REFERENCE 2: 128:102282

REFERENCE 3: 128:74952

REFERENCE 4: 128:39553

REFERENCE 5: 128:39550

REFERENCE 6: 128:33838

REFERENCE 7: 127:351317

REFERENCE 8: 127:339324

REFERENCE 9: 127:331288

REFERENCE 10: 127:331270

L17 ANSWER 8 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 23979-41-1 REGISTRY
CN **2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (R)- (8CI, 9CI)** (CA INDEX NAME)
OTHER NAMES:
CN **(-)-2-(6-Methoxy-2-naphthyl)propionic acid**
CN **(-)-6-Methoxy-.alpha.-methyl-2-naphthalenacetic acid**
CN (-)-Naproxen
CN (R)-(-)-Naproxen
CN **(R)-2-(6-Methoxy-2-naphthyl)propionic acid**
CN (R)-Naproxen
CN l-Naproxen
FS STEREOSEARCH
MF **C14 H14 O3**
CI COM
LC STN Files: BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CHEMINFORMRX, CHEMLIST, CIN, CJACS, DRUGPAT, IFICDB, IFIPAT, IFIUDB, IPA, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



187 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
188 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:119736

REFERENCE 2: 128:102282

REFERENCE 3: 128:97725

REFERENCE 4: 127:351317

REFERENCE 5: 127:331575

REFERENCE 6: 127:316488

REFERENCE 7: 127:311497

REFERENCE 8: 127:283465

REFERENCE 9: 127:229214

REFERENCE 10: 127:86184

L17 ANSWER 9 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN **22204-53-1** REGISTRY
CN **2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (S)-(9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (+)-(8CI)**
OTHER NAMES:
CN **(+)-2-(6-Methoxy-2-naphthyl)propionic acid**
CN **(+)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid**
CN (+)-Naproxen
CN (S)-(+)-Naproxen
CN **(S)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid**
CN (S)-Naproxen
CN CG 3117
CN **d-2-(6-Methoxy-2-naphthyl)propionic acid**
CN d-Naproxen
CN Equiproxen
CN Naixan
CN Naprosyn
CN Naproxen
CN **S-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid**
CN **S-2-(6-Methoxy-2-naphthyl)propionic acid**
FS STEREOSEARCH
MF **C14 H14 O3**
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CJACS, CSCHEM, DETHERM*, DDFU, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PNI, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



2239 REFERENCES IN FILE CA (1967 TO DATE)
91 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2241 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:145369

REFERENCE 2: 128:145263

REFERENCE 3: 128:132449

REFERENCE 4: 128:132433

REFERENCE 5: 128:132421

REFERENCE 6: 128:132399

REFERENCE 7: 128:123562

REFERENCE 8: 128:119736

REFERENCE 9: 128:119657

REFERENCE 10: 128:119562

L17 ANSWER 10 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN 22161-81-5 REGISTRY
CN **Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, (S)- (9CI)**
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Hydratropic acid, m-benzoyl-, (+)- (8CI)**
OTHER NAMES:
CN **(+)-(S)-m-Benzoylhydratropic acid**
CN **(+)-2-(3-Benzoylphenyl)propionic acid**
CN **(+)-3-Benzoyl-.alpha.-methylbenzeneacetic acid**
CN **(+)-3-Benzoylhydratropic acid**
CN (+)-Ketoprofen
CN **(2S)-2-(3-Benzoylphenyl)propionic acid**
CN **(S)-(+)-2-(3-Benzoylphenyl)propionic acid**
CN **(S)-2-(3-Benzoylphenyl)propionic acid**
CN (S)-Ketoprofen
CN Dexketoprofen
CN S(+)-Ketoprofen
FS STEREOSEARCH
MF **C16 H14 O3**
CI COM
LC STN Files: AGRICOLA, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CEN, CHEMINFORMRX, CHEMLIST, CIN, CJACS, CSCHEM, DDFU, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, IFICDB, IFIPAT, IFIUDB, IPA, PHAR, PNI, PROMT, RTECS*, TOXLINE, TOXLIT, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



235 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
236 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:136065

REFERENCE 2: 128:135908

REFERENCE 3: 128:119736

REFERENCE 4: 128:102282

REFERENCE 5: 128:97725

REFERENCE 6: 128:85960

REFERENCE 7: 128:53252

REFERENCE 8: 127:362485

REFERENCE 9: 127:351317

REFERENCE 10: 127:302703

L17 ANSWER 11 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN **22071-15-4** REGISTRY
CN **Benzeneacetic acid, 3-benzoyl-.alpha.-methyl- (9CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Hydratropic acid, m-benzoyl- (8CI)**
OTHER NAMES:
CN **(.+-.)-2-(3-Benzoylphenyl)propionic acid**
CN **(.+-.)-3-Benzoyl-.alpha.-methylbenzeneacetic acid**
CN (.+-.)-Ketoprofen
CN **(.+-.)-m-Benzoylhydratropic acid**
CN (RS)-Ketoprofen
CN **.alpha.-(3-Benzoylphenyl)propionic acid**
CN 19583RP
CN **2-(3-Benzoylphenyl)propionic acid**
CN **2-(m-Benzoylphenyl)propionic acid**
CN **3-Benzoyl-.alpha.-methylbenzeneacetic acid**
CN **3-Benzoylhydratropic acid**
CN Alrheumun
CN Aneol
CN Capisten

CN Epatec
CN Ketoprofen
CN Ketoprofene
CN Ketoprophen
CN **m-Benzoylhydratropic acid**
CN Orudis
CN Oruvail
CN Profenid
CN R.P. 19583
CN Racemic ketoprofen
CN RU 4733
FS 3D CONCORD
DR 172964-50-0, 22161-86-0
MF **C16 H14 O3**
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CSCHEM, DDFU, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PHAR, PNI, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



1747 REFERENCES IN FILE CA (1967 TO DATE)
57 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1754 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:145369

REFERENCE 2: 128:145263

REFERENCE 3: 128:136517

REFERENCE 4: 128:135908

REFERENCE 5: 128:132449

REFERENCE 6: 128:132421

REFERENCE 7: 128:123397

REFERENCE 8: 128:119736

REFERENCE 9: 128:119657

REFERENCE 10: 128:119646

L17 ANSWER 12 OF 12 REGISTRY COPYRIGHT 1998 ACS
RN **15687-27-1** REGISTRY
CN **Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (9CI)**
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Hydratropic acid, p-isobutyl- (7CI, 8CI)
OTHER NAMES:
CN (.+-.)-.alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid
CN (.+-.)-2-(p-Isobutylphenyl)propionic acid
CN (.+-.)-Ibuprofen
CN (.+-.)-Ibuprophen
CN (RS)-Ibuprofen
CN .alpha.-(4-Isobutylphenyl)propionic acid
CN .alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid
CN 2-(4'-Isobutylphenyl)propionic acid
CN 2-(4-Isobutylphenyl)propanoic acid
CN 2-(p-Isobutylphenyl)propionic acid
CN 4-Isobutylhydratropic acid
CN Advil
CN Brufen
CN dl-Ibuprofen
CN Ibufen
CN Ibuprofen
CN IP 82
CN Motrin
CN Nuprin
CN Nurofen
CN p-Isobutyl-2-phenylpropionic acid
CN p-Isobutylhydratropic acid
CN Paduden
CN Proflex
CN RD 13621
CN Rufin
CN Unipron
FS 3D CONCORD
DR 58560-75-1
MF **C13 H18 O2**
CI COM
LC STN Files: AGRICOLA, AIDSLINE, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CBNB, CIN, CJACS, CSCHEM, DDFU, DIPPR*, DRUGPAT, DRUGU, EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PHAR, PNI, PROMT, RTECS*, SPECINFO, TOXLINE, TOXLIT, USAN, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: DSL**, EINECS**, TSCA**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



3854 REFERENCES IN FILE CA (1967 TO DATE)
112 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3860 REFERENCES IN FILE CAPLUS (1967 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 128:145447

REFERENCE 2: 128:145369

REFERENCE 3: 128:145364

REFERENCE 4: 128:145355

REFERENCE 5: 128:145263

REFERENCE 6: 128:145258

REFERENCE 7: 128:145240

REFERENCE 8: 128:136083

REFERENCE 9: 128:132519

REFERENCE 10: 128:132458

=> d his l18-

(FILE 'HCAPLUS' ENTERED AT 16:11:16 ON 20 MAR 1998)
L18 7002 S L17
L19 2 S L17 (L) (ALKYL AMMONIUM OR ALKYLAMMONIUM OR AMMONIUMALK
L20 2 S L18 (L) (ALKYL AMMONIUM OR ALKYLAMMONIUM OR AMMONIUMALK
L21 2 S L19,L20
E GENTILE M/AU
L22 22 S E3-E6,E8
E BOLTRI L/AU
L23 12 S E3,E4
E CLAVENNA G/AU
L24 32 S E3,E4
L25 6 S L18 AND L22-L24
L26 5 S L25 NOT L21
L27 1 S L25 AND L21

FILE 'REGISTRY' ENTERED AT 16:16:35 ON 20 MAR 1998
E LYSINE/CN
L28 2 S E3
E D-LYSINE/CN
L29 1 S E3
E DL-LYSINE/CN
L30 1 S E3
L31 3 S L28-L30
SEL RN 1-3
L32 1674 S E1-E3/CRN
SEL RN L17 1-12
L33 624 S E4-E15/CRN
L34 33 S L32 AND L33
L35 22 S L34 AND 2/NC
L36 11 S L34 NOT L35

← from applicants

```
L37           4 S L36 AND H2O
L38          26 S L35,L37

     FILE 'HCAPLUS' ENTERED AT 16:19:15 ON 20 MAR 1998
L39          95 S L38
L40           5 S L39 AND PARENTERAL?
L41          11 S L21,L25-L27,L40
L42           2 S OSMOLAR? AND L18
                SEL HIT RN L41 1-11

     FILE 'REGISTRY' ENTERED AT 16:21:30 ON 20 MAR 1998
L43          13 S E16-E29
L44           6 S L43 NOT L17

     FILE 'REGISTRY' ENTERED AT 16:22:01 ON 20 MAR 1998

=> d ide can 144 tot


L44  ANSWER 1 OF 6  REGISTRY  COPYRIGHT 1998 ACS
RN   173011-11-5  REGISTRY
CN   Lysine, mono(3-benzoyl-.alpha.-methylbenzeneacetate) (9CI)  (CA
     INDEX NAME)
OTHER CA INDEX NAMES:
CN   Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, compd. with lysine
     (1:1) (9CI)
CN   Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, compd. with DL-lysine
     (1:1)
CN   DL-Lysine, mono(3-benzoyl-.alpha.-methylbenzeneacetate)
MF   C16 H14 O3 . C6 H14 N2 O2
SR   CAS Registry Services
LC   STN Files:   CA, CAPLUS, TOXLIT

     CM   1

     CRN  22071-15-4
     CMF  C16 H14 O3
```




```
     CM   2

     CRN  70-54-2
     CMF  C6 H14 N2 O2
```



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:126655

L44 ANSWER 2 OF 6 REGISTRY COPYRIGHT 1998 ACS
RN **167300-66-5** REGISTRY
CN L-Lysine, mono[(R)-3-benzoyl-.alpha.-methylbenzeneacetate] (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, (R)-, compd. with L-lysine (1:1) (9CI)
FS STEREOSEARCH
MF C16 H14 O3 . C6 H14 N2 O2
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXLIT

CM 1

CRN 56105-81-8
CMF C16 H14 O3

Absolute stereochemistry.



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:126655

REFERENCE 2: 123:169348

L44 ANSWER 3 OF 6 REGISTRY COPYRIGHT 1998 ACS
RN **162929-63-7** REGISTRY
CN L-Lysine, mono[(.alpha.S)-3-benzoyl-.alpha.-methylbenzeneacetate] (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, (S)-, compd. with L-lysine (1:1) (9CI)
CN L-Lysine, mono[(S)-3-benzoyl-.alpha.-methylbenzeneacetate]
FS STEREOSEARCH
MF C16 H14 O3 . C6 H14 N2 O2
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXLIT

CM 1

CRN 22161-81-5
CMF C16 H14 O3

Absolute stereochemistry.



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1967 TO DATE)
4 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:126655

REFERENCE 2: 126:216664

REFERENCE 3: 125:142274

REFERENCE 4: 122:274104

L44 ANSWER 4 OF 6 REGISTRY COPYRIGHT 1998 ACS

RN **151237-76-2** REGISTRY
CN L-Lysine, bis[(R)-3-benzoyl-.alpha.-methylbenzeneacetate] (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, (R)-, compd. with L-lysine (2:1) (9CI)
FS STEREOSEARCH
MF C16 H14 O3 . 1/2 C6 H14 N2 O2
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXLIT

CM 1

CRN 56105-81-8
CMF C16 H14 O3

Absolute stereochemistry.



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 119:256522

L44 ANSWER 5 OF 6 REGISTRY COPYRIGHT 1998 ACS
RN **76201-68-8** REGISTRY
CN L-Lysine, mono[(.alpha.S)-6-methoxy-.alpha.-methyl-2-naphthaleneacetate] (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2-Naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (S)-, compd. with L-lysine (1:1) (9CI)
CN L-Lysine, mono[(S)-6-methoxy-.alpha.-methyl-2-naphthaleneacetate]
OTHER NAMES:

CN Naproxen lysine
FS STEREOSEARCH
MF C14 H14 O3 . C6 H14 N2 O2
LC STN Files: BIOSIS, CA, CAPLUS, IPA, TOXLINE, TOXLIT

CM 1

CRN 22204-53-1
CMF C14 H14 O3

Absolute stereochemistry. Rotation (+).



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



8 REFERENCES IN FILE CA (1967 TO DATE)
8 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 128:43357

REFERENCE 2: 128:26847

REFERENCE 3: 126:216664

REFERENCE 4: 120:143903

REFERENCE 5: 115:263220

REFERENCE 6: 112:229436

REFERENCE 7: 110:218941

REFERENCE 8: 94:52802

L44 ANSWER 6 OF 6 REGISTRY COPYRIGHT 1998 ACS
RN **57469-78-0** REGISTRY
CN L-Lysine, mono(3-benzoyl-.alpha.-methylbenzeneacetate) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-, compd. with L-lysine (1:1) (9CI)
OTHER NAMES:
CN Ketoprofen L-lysinate
CN Ketoprofen lysine salt
CN L-Lysine, 3-benzoyl-.alpha.-methylbenzeneacetate
CN Lysine m-benzoylhydratropate
FS STEREOSEARCH
DR 96407-23-7
MF C16 H14 O3 . C6 H14 N2 O2
LC STN Files: BEILSTEIN*, BIOBUSINESS, CA, CAPLUS, CIN, DDFU, DRUGPAT, DRUGU, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PNI, PROMT, TOXLINE, TOXLIT, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 22071-15-4
CMF C16 H14 O3



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



16 REFERENCES IN FILE CA (1967 TO DATE)
16 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 127:126655

REFERENCE 2: 127:126404

REFERENCE 3: 127:86130

REFERENCE 4: 126:14569

REFERENCE 5: 125:284962

REFERENCE 6: 125:48899

REFERENCE 7: 123:74438

REFERENCE 8: 122:274104

REFERENCE 9: 121:18187

REFERENCE 10: 117:239847

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:22:52 ON 20 MAR 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1967 - 20 Mar 1998 VOL 128 ISS 12
FILE LAST UPDATED: 20 Mar 1998 (980320/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file now supports REG1stRY for direct browsing and searching of all non-structural data from the REGISTRY file. Enter HELP FIRST for more information.

=> d bib abs hitrn tot l41

L41 ANSWER 1 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1998:112329 HCAPLUS
TI Preparation of 2-arylalkanoic acids
IN Mantovanini, Marco; Allegretti, Marcello; **Clavenna, Gaetano** ; Gandolfi, Carmelo
PA Dompe' S.P.A., Italy; Mantovanini, Marco; Allegretti, Marcello; Clavenna, Gaetano; Gandolfi, Carmelo
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
PI WO 9805623 A1 980212
DS W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 97-EP4050 970725
PRAI IT 96-MI1683 960802
DT Patent
LA English
AB 3-R1C6H4CHRCO2H [R = H or alkyl; R1 = (un)substituted alkyl, -aryl(oxy), -aroyl] were prepd. Thus, 4-(HO)C6H4COPh was etherified by BrCH2CH:CHMe and the product subjected to Claisen rearrangement

to give, in 3 addnl. steps, Ketoprofen.
IT INDEXING IN PROGRESS
IT **22071-15-4P**, Ketoprofen
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of 2-arylalkanoic acids)

L41 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:526676 HCAPLUS
DN 127:126655
TI **Parenteral** pharmaceutical compositions containing ammoniumalkyl salts of 2-arylpropionic acids
IN **Gentile, Marco; Boltri, Luigi; Clavenna, Gaetano**
PA Dompe' S.P.A., Italy; Gentile, Marco; Boltri, Luigi; Clavenna, Gaetano
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
PI WO 9724114 A1 970710
DS W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 96-IB1461 961223
PRAI IT 95-MI2777 951228
DT Patent
LA English
AB A pharmaceutical compn. for **parenteral** administration having anti-inflammatory and analgesic properties which contain, as active principle, alkylammonium salts of 2-arylpropionic acids is disclosed. Citric acid 37.5 and sodium hydroxide 22.5 g were dissolved in 12 L of water followed by addn. of 1.2 kg of (R,S)-ketoprofen salt of D,L-lysine and adjusting the pH to 7.0-7.5. After complete dissoln. of the salt the vol. was brought to 15 L with water and deaerated with N and filtered. The soln. was filled into 2 mL phials under N and sealed.
IT **15687-27-1D**, Ibuprofen, **alkylammonium** salts
22071-15-4D, Ketoprofen, **alkylammonium** salts
22204-53-1D, Naproxen, **alkylammonium** salts
33005-95-7D, Tiaprofenic acid, **alkylammonium** salts
57469-78-0 162929-63-7 167300-66-5
173011-11-5
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**parenteral** pharmaceutical compns. contg. **ammoniumalkyl** salts of arylpropionic acids)

L41 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1997:455683 HCAPLUS
DN 127:126404
TI Intramuscular bioavailability of ketoprofen lysine salt in horses
AU Anfossi, P.; Villa, R.; Montesissa, C.; Carli, S.
CS Department of Public Veterinary Health and Animal Pathology, Faculty of Veterinary Medicine, University of Bologna, Ozzano Emilia, 40064, Italy
SO Vet. Q. (1997), 19(2), 65-68
CODEN: VEQUDU; ISSN: 0165-2176
PB Royal Netherlands Veterinary Association

= inventive entity

DT Journal
LA English
AB Lysine salts are often used in human pharmaceuticals to increase the soly. and absorption of acidic drugs when these are administered **parenterally**. In this study the i.m. bioavailability of ketoprofen administered as the lysine salt was evaluated in horses treated i.v. and i.m. (2.2 mg/kg active substance) in a cross-over study. The absorption rate of ketoprofen administered as the lysine salt was rather low: the mean residence time increased from 31.7 min after i.v. injection to 128.9 min (after i.m. injection), and the bioavailability was high (mean 92.4%). The calcd. steady state plasma concns. of ketoprofen during multiple dosage were much higher after i.m. (0.106 g/mL) than after i.v. (0.066 .mu.g/mL) administration. I.m. injections of the ketoprofen lysine salt can therefore be given to horses, which are particularly prone to develop soft tissue reactions, since use of the lysine salt markedly reduced local irritation at the injection site.
IT **57469-78-0**, Ketoprofen lysine salt
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(i.m. bioavailability of ketoprofen lysine salt in horses)

L41 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1996:660928 HCAPLUS
DN 125:284962
TI Pharmaceutical formulations in form of thixotropic gel
IN **Boltri, Luigi**; Coppola, Antonietta; **Gentile, Marco**; **Clavenna, Gaetano**
PA Dompe S.P.A., Italy
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
PI EP 733357 A1 960925
DS R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
AI EP 96-104268 960318
PRAI IT 95-MI568 950322
DT Patent
LA English
AB The present invention relates to a topical formulation of gel-like consistency, but nebulizable by a mech. pump, contg. colloidal silica as gellant. For example, a topical gel contained ketoprofen lysine salt 15, colloidal silica 5, propylene glycol 5, Tween 80 0.5, Na nipagin 0.1, Nerolene lavender 0.1, and demineralized water to 100 %.
IT **22204-53-1**, Naproxen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulations in form of thixotropic gel)

L41 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1995:772559 HCAPLUS
DN 123:169348
TI Salts of 2-(3-benzoylphenyl)propionic acid with achiral and chiral organic bases and antiinflammatory pharmaceutical compositions containing them
IN Bosone, Enrico; **Clavenna, Gaetano**; Gandolfi, Carmelo; Mantovanini, Marco; Curti, Roberto
PA Dompe'Farmaceutici SPA, Italy; Dompe SPA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

in future IDS

PI WO 9420449 A1 940915
DS W: AU, BB, BG, BR, CA, CN, CZ, FI, HU, JP, KP, KR, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 94-IT20 940307
PRAI IT 93-MI447 930309
IT 94-MI348 940225
DT Patent
LA English
AB The salts of S(+) 2-(3-benzoylphenyl)propionic acid and of R(-) 2-(3-benzoylphenyl)propionic acid with an achiral, org. base [e.g., tris(hydroxymethyl)aminomethane] or a chiral org. base [e.g., D-lysine, L-lysine, L-arginine, (R)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol, and (S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol], useful as antiinflammatory agents (no data), are prepd.
IT **22161-81-5P**, (S)-Ketoprofen **56105-81-8P**, (R)-Ketoprofen
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(diastereomeric salts of 2-(3-benzoylphenyl)propionic acid with achiral and chiral org. bases and antiinflammatory pharmaceutical compns. contg. them)
IT **22161-86-0**, (.+-.)-2-(3-Benzoylphenyl)propionic acid
RL: RCT (Reactant)
(diastereomeric salts of 2-(3-benzoylphenyl)propionic acid with achiral and chiral org. bases and antiinflammatory pharmaceutical compns. contg. them)

L41 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1994:564006 HCAPLUS
DN 121:164006
TI Pharmaceutical compositions including a drug, a crosslinked polymeric substance, an oil, and a surface active agent.
IN Carli, Fabio; Lombardi, Daniela; Esposito, Pierandrea; Dobetti, Luca; **Boltri, Luigi**
PA Vectorpharma International S.P.A., Italy
SO Eur. Pat. Appl., 12 pp.
CODEN: EPXXDW
PI EP 598337 A2 940525
DS R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, PT
AI EP 93-118278 931111
PRAI IT 92-MI2603 921113
DT Patent
LA English
AB Pharmaceutical compns. including a slightly sol. drug incorporated in a water-swellable, but water-insol. cross-linked polymer, a surface active agent, and an oil show much improved dissoln. and, consequently, bioavailability in respect to the drug as is or used with a polymeric carrier of said type. Ubidecarenone was dissolved in a 50% mixt. of Lexol PG 865 and Tween 80 and the soln. thus obtained was added at 50.degree. to crospovidone so as to secure a drug/polymer ratio equal to 1:3 by wt. and the product obtained was allowed to stand at room temp. for 24 h.
IT **15687-27-1**, Ibuprofen **22204-53-1**, Naproxen
RL: BIOL (Biological study)
(pharmaceutical compns. contg. crosslinked polymers and oils and surfactants and)

L41 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1994:143903 HCAPLUS
DN 120:143903
TI Naproxen lysinate part II - preformulation data
AU Lalla, J. K.; Sharma, Anju H.
CS Dep. Pharm., Principal K. M. Kundnani Coll. Pharm., Bombay, 400 018, India
SO Indian Drugs (1994), 31(1), 9-15
CODEN: INDRBA; ISSN: 0019-462X
DT Journal
LA English
AB An attempt was made to increase the soly. of naproxen through the synthesis of a prodrug. Lysine was used as the solubilizing progroup. Naproxen lysinate was synthesized which possessed the attributes of enhanced aq. soly. Preformulation data were detd. for the compd. to assess its suitability for incorporation into a **parenteral** dosage form. Stability profiles of aq. solns. of the prodrug under various conditions were detd.
IT **76201-68-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and soly. and stability of, preformulation in relation to)

L41 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1993:656522 HCAPLUS
DN 119:256522
TI Pharmaceutical compositions containing optically pure R(-) ketoprofen
IN Young, James W.; Gray, Nancy M.; Wechter, William J.
PA Sepracor, Inc., USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
PI WO 9317677 A1 930916
DS W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NL, PT, SE, SN, TD, TG
AI WO 93-US2126 930308
PRAI US 92-848458 920309
US 93-24728 930301
DT Patent
LA English
AB Pharmaceutical compns. contg. optically pure R(-) ketoprofen (I) are prepd. for the treatment of pain and pyrexia without the adverse effects which are assocd. with the administration of racemic I. I Me ester (prepn. is given) was combined with ethanolic KOH soln. and pH was adjusted to 2, extd. with Et2O, dried, solvent removed and crude I was recrystd. Mice were given .gtoreq.2 dose of 30mg I/kg orally and were then challenged with a soln. of phenyl-p-benzoquinone i.p. and were obsd. for stretch-writhing syndrome. At least a 50% decrease was demonstrated in the no. of writhing in 100% of animals. Formulation of a capsule contg. I is given.
IT **151237-76-2P**
RL: PREP (Preparation)
(prepn. of, pharmaceutical compn. contg.)

L41 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 1998 ACS

AN 1988:582934 HCAPLUS
DN 109:182934
TI A rapid and highly predictive in vitro assay for nonsteroidal anti-inflammatory agents
AU Luzzani, F.; Ventura, P.; Zuccari, G.; **Clavenna, G.**
CS Anal. Chem., Camillo Corvi S.p.A., Piacenza, Italy
SO Int. J. Tissue React. (1988), 10(2), 79-83
CODEN: IJTEDP; ISSN: 0250-0868
DT Journal
LA English
AB The inhibition of the prodn. of malonyldialdehyde (MDA) in guinea pig lung homogenates, incubated in the presence of 50 .mu.M arachidonic acid and 1.4 mM adrenaline, was exploited as a simple and reliable assay to test in vitro nonsteroidal anti-inflammatory agents (NSAIA). The inhibitory potencies of a series of ref. NSAIA, which correlated fairly well with in vivo anti-inflammatory activity as detd. by carrageenin edema, are reported. The specificity of the assay was also evaluated by testing up to 40 misc. drugs: none of these reduced MDA prodn.
IT **15687-27-1**, Ibuprofen **22071-15-4**, Ketoprofen **22204-53-1**, Naproxen
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inflammation inhibition by, malonyldialdehyde formation in lung in relation to)

L41 ANSWER 10 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1987:84205 HCAPLUS
DN 106:84205
TI Process for the preparation of naproxen by resolution of (.+-.)-6-methoxy-.alpha.-methyl-2-naphthaleneacetic acid
IN Bernini, Giuseppe
PA Secifarma S.p.A., Italy
SO U.S., 3 pp.
CODEN: USXXAM
PI US 4625054 A 861125
AI US 85-786669 851011
PRAI IT 84-23659 841120
DT Patent
LA English
GI



I

AB (.+-.)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid [(.+-.)-I] is resolved by treatment with L-threo-(+)-2-amino-1-(4-nitrophenyl)-1,3-propanediol (II) or L-threo-(+)-2-amino-1-[4-(methylthio)phenyl]-1,3-propanediol (III) in an acid-amine ratio of 3-4.5:1, and in an inert solvent wherein (-)-I.II or (-)-I.III is less sol. than the corresponding (+)-I salt. The pptd. (-)-I salt is filtered, and the

filtrate treated with NH3 or an alkylamine to ppt. remaining (.+-.)-I as the ammonium or alkylammonium salt. This is sepd. and the filtrate is treated with a 2nd base to give a poorly sol. salt of (+)-I, which is isolated and decompd. by mineral or org. acid to give (+)-I (naproxen). (.+-.)-I and II were dissolved in refluxing 1:1 MeOH-PhMe, and the mixt. was cooled to 20.degree. to ppt. the complex salt 2(-)-I.II, which was sepd. Aq. 28% NH3 was added to the mother liquors to ppt. (.+-.)-I.NH3, and the filtrate from this was treated with N-methylglucamine (IV) at the b.p. and cooled to give cryst. (+)-I.IV. Acidification of the latter in aq. soln. pptd. (+)-I having [.alpha.]D > +66.degree..

IT **26159-31-9DP**, (.+-.)-6-Methoxy-.alpha.-methyl-2-naphthaleneacetic acid, **alkylammonium** salts
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and sepn. of, in prodn. of naproxen)

L41 ANSWER 11 OF 11 HCAPLUS COPYRIGHT 1998 ACS
AN 1981:162745 HCAPLUS
DN 94:162745
TI Lysine m-benzoylhydratropate and pharmaceutical compositions containing it
PA Dompe Farmaceutici S.p.A., Italy
SO Belg., 18 pp.
CODEN: BEXXAL
PI BE 882889 800818
PRAI IT 77-23465 770512
DT Patent
LA French
GI



I

AB Lysine m-benzoylhydratropate (I) [**57469-78-0**], m. 145-9.degree., was prepd. and used as an antiinflammatory agent, analgesic, and antiagglutinant having superior properties to that of m-benzoylhydratropic acid (II). I also has an ulcerogenic activity. I was prepd. by treating 1 mol II with 1 mol L-lysine. The toxicity, teratogenic, cardiovascular, antiinflammatory, analgesic, antipyretic, ulcerogenic, and antiagglutinant activities of I are reported. I may be administered orally or **parenterally**.

IT **57469-78-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and pharmacol. properties of)

=> fil wpids

FILE 'WPIDS' ENTERED AT 16:24:14 ON 20 MAR 1998
COPYRIGHT (C) 1998 DERWENT INFORMATION LTD

FILE LAST UPDATED: 16 MAR 1998 <19980316/UP>
>>>UPDATE WEEKS:

MOST RECENT DERWENT WEEK 199811 <199811/DW>
DERWENT WEEK FOR CHEMICAL CODING: 199806
DERWENT WEEK FOR POLYMER INDEXING: 199808
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS - SEE HELP COST FOR DETAILS <<<
>>> CHANGES TO DWPI COVERAGE - SEE NEWS <<<

=> d l8 que

L8 1 SEA FILE=WPIDS ABB=ON PLU=ON IT95-MI2777/PRN

=> d l8 all

L8 ANSWER 1 OF 1 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 97-363437 [33] WPIDS
DNC C97-116439
TI Stable, safe parenteral antiinflammatory and analgesic composition - comprising aryl propionic acid alkyl ammonium salt in preservative-free aqueous solution kept under inert gas, used e.g. for treating rheumatoid arthritis.
DC B05
IN BOLTRI, L; CLAVENNA, G; GENTILE, M
PA (DOMP-N) DOMPE SPA
CYC 64
PI WO 9724114 A1 970710 (9733)* EN 18 pp A61K031-19
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG
W: AL AM AU BB BG BR CA CN CZ EE GE HU IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL SG SI SK TR TT UA US UZ VN
AU 9710698 A 970728 (9746) A61K031-19
NO 9703921 A 970826 (9749) A61K031-205
CZ 9702643 A3 971112 (9801) A61K031-19
EP 814797 A1 980107 (9806) EN A61K031-19
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
ADT WO 9724114 A1 WO 96-IB1461 961223; AU 9710698 A AU 97-10698 961223; NO 9703921 A WO 96-IB1461 961223, NO 97-3921 970826; CZ 9702643 A3 WO 96-IB1461 961223, CZ 97-2643 961223; EP 814797 A1 EP 96-940698 961223, WO 96-IB1461 961223
FDT AU 9710698 A Based on WO 9724114; CZ 9702643 A3 Based on WO 9724114; EP 814797 A1 Based on WO 9724114.
PRAI **IT 95-MI2777 951228**
REP 1.Jnl.Ref ; DE 2508895; EP 136470; EP 70714; GB 2059768; US 4877620; US 5206262; WO 8904658; WO 9316689; WO 9317677; WO 9420449
IC ICM A61K031-19; A61K031-205
ICS A61K009-08; A61K031-195; A61K031-38
AB WO 9724114 A UPAB: 970813
An antiinflammatory and analgesic composition (A) for parenteral administration contains an alkylammonium salt (I) of a 2-arylpropionic acid (II) in an aqueous solution having osmolarity 270-310 mOsm/kg and pH 7.0-7.5. The solution is free of preservatives and carriers, and is prepared and kept in an inert gas atmosphere. (II) is ketoprofen, ibuprofen, naproxen or tiaprofenic acid, all in racemic or enantiomeric form. Also claimed is the preparation of the composition by dissolving (I) in water for injection at pH 7.0-7.5 in an inert gas atmosphere in the absence of light.

USE - (A) are useful e.g. for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute painful articular and periarticular symptoms of the musculoskeletal system, gout, dysmenorrhoea, pain and inflammation during or following orthopaedic operations, pain in terminal cancer patients and in individual treatments in association with muscle relaxants, pain killers or central analgesics.

ADVANTAGE - (A) cause only minor discomfort on administration, compared with the (possibly intense) pain on administration of prior art parenteral formulations of (II); and are free of the side-effects of topical administration of (II). They are stable, and safe and convenient to use. (A) remain clear, and any appearance of opalescence is an indicator of incorrect storage (i.e. a useful and sensitive index of quality).

Dwg.0/0

FS CPI
FA AB; DCN
MC CPI: B07-B01; B10-A22; B10-C03; B10-C04B; B10-C04C; B12-M07; B14-C01; B14-C02; B14-C03; B14-C09; B14-J05; B14-N14

=> d his l45-

(FILE 'REGISTRY' ENTERED AT 16:22:01 ON 20 MAR 1998)

FILE 'HCAPLUS' ENTERED AT 16:22:52 ON 20 MAR 1998

FILE 'WPIDS' ENTERED AT 16:24:03 ON 20 MAR 1998

FILE 'WPIDS' ENTERED AT 16:24:14 ON 20 MAR 1998

```
L45          24 S R06842/DCN
L46          17 S R07099/DCN
L47          11 S R07101/DCN
L48          42 S R06547/DCN
L49        2547 S R01514/DCN
L50        2391 S R00419/DCN
L51           1 S 9733-25401/DCN
L52           3 S B10-A22/MC AND B10-C03/MC AND B10-C04B/MC AND B10-C04C/
L53         129 S B10-A22/MC AND B10-C03/MC
L54          33 S B10-A22/MC AND B10-C04B/MC
L55          43 S B10-A22/MC AND B10-C04C/MC
L56         185 S L53-L55
L57           8 S PARENT? AND L56
L58          44 S PARENTER? AND L45-L50
L59           2 S L58 AND B10-A22/MC
L60           9 S L52,L57,L59
L61           6 S L56 AND B12-M07/MC
L62          14 S L61,L60
L63        1353 SEA R023/M0,M1,M2,M3,M4,M5,M6 AND (L45 OR L46 OR L47 OR L
                77 OR L49 OR L50 OR L53 OR L54 OR L55 OR L56 OR L57 OR L8
                7 OR L59 OR L60 OR L61 OR L62)
L64           3 S L63 AND L62
L65          34 S B10-A22/MC AND L45-L51
L66          36 S L52,L65
L67           3 S L66 AND PARENTER?
L68           2 S L67 NOT L8
```

ammon. must be present in parent

=> d bib abs tot

L68 ANSWER 1 OF 2 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 97-387278 [36] WPIDS
DNC C97-124318
TI Carnitine or alkanoyl-carnitine in lipid metabolism disorders - e.g. obesity, cardiovascular, thromboembolic, atherosclerotic, as compositions with hydroxy-citric or pantothenic acids.
DC B05
IN CAVAZZA, C; CAVAZZA, G
PA (SIGT) SIGMA-TAU IND FARM RIUNITE SPA
CYC 21
PI EP 787489 A2 970806 (9736)* EN 9 pp
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
JP 09176004 A 970708 (9737) 8 pp
ZA 9610508 A 970827 (9740) 26 pp
CA 2192899 A 970616 (9742)
EP 787489 A3 970910 (9746)
ADT EP 787489 A2 EP 96-830617 961211; JP 09176004 A JP 96-330682 961211; ZA 9610508 A ZA 96-10508 961213; CA 2192899 A CA 96-2192899 961213; EP 787489 A3 EP 96-830617 961211
PRAI IT 95-RM824 951215
AN 97-387278 [36] WPIDS
AB EP 787489 A UPAB: 970909
Orally, **parenterally**, transdermally, or rectally administrable composition, for treating cardiovascular, thromboembolic, atherosclerotic or hyper-lipidaemic disorders, obesity, and to decrease appetite, comprises:
(a) L-carnitine of its 2-8C, preferably 2-6C alkanoyl L-carnitine or their salts, and
(b) hydroxycitric (HCA) or pantothenic acids (PTA) or their derivatives, as active ingredients with an excipient.
USE - The two active agents both exert an action on lipid metabolism by different mechanisms, and are synergistic. Suitable formulations are in solid (tablet, capsule), semisolid, powder, granular, liquid in vials or as liposomes (all claimed).
Dwg.0/0

L68 ANSWER 2 OF 2 WPIDS COPYRIGHT 1998 DERWENT INFORMATION LTD
AN 95-053613 [08] WPIDS
DNC C95-024404
TI New naphthalene or heterocyclic analogue cpds. - used as glycoprotein IIb and IIIa antagonists and platelet aggregation inhibitors, e.g. for treating angina.
DC B02
IN FISHER, M J; HAPP, A M; JAKUBOWSKI, J A; KINNICK, M D; KLINE, A D; MORIN, J M; SALL, D J; SKELTON, M A; VASILEFF, R T; FISCHER, M J; SKELTON, A M
PA (ELIL) LILLY & CO ELI
CYC 28
PI EP 635492 A1 950125 (9508)* EN 108 pp
R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
NO 9402734 A 950123 (9511)
AU 9467500 A 950202 (9513)
CA 2128348 A 950123 (9516)
FI 9403478 A 950123 (9516)
BR 9402916 A 950411 (9521)
CZ 9401740 A3 950913 (9545)

ZA 9405251 A 960327 (9619) 173 pp
JP 08188564 A 960723 (9639) 78 pp
US 5618843 A 970408 (9720) 62 pp
HU 70397 T 951030 (9732)
CN 1108248 A 950913 (9733)
NZ 264060 A 970822 (9741)

ADT EP 635492 A1 EP 94-305241 940718; NO 9402734 A NO 94-2734 940721; AU 9467500 A AU 94-67500 940715; CA 2128348 A CA 94-2128348 940719; FI 9403478 A FI 94-3478 940722; BR 9402916 A BR 94-2916 940722; CZ 9401740 A3 CZ 94-1740 940719; ZA 9405251 A ZA 94-5251 940718; JP 08188564 A JP 94-170747 940722; US 5618843 A CIP of US 93-96220 930722, US 94-255821 940708; HU 70397 T HU 94-2156 940721; CN 1108248 A CN 94-109191 940722; NZ 264060 A NZ 94-264060 940721

PRAI US 93-96220 930722; US 94-255821 940708

AN 95-053613 [08] WPIDS

AB EP 635492 A UPAB: 950301

Naphthalene derivs. or heterocyclic analogues of formula (I), contg. acidic and basic substits. and their salts, solvates and prodrugs are new: B1-B4 = C, O, S or N, provided that at least two = C; R3 = acidic gp; n - 2-6; R6 = H, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, OH, alkoxy, aralkoxy, opt. substd. amino, carbamyl, COOH, acyl, CN, halo, NO2, SO3H = O or = S; provided that if Rp = O or S then only one of B1-B4 can be N; A1-A4 = C, O, S or N, provided that at least two = C; m = 2-6; R10 = H, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, OH, alkoxy, aralkoxy, COOH, acyl, CN, halo, NO2, SO3H = O o = S; provided that only one R10 may be O or S; L = direct bond; or opt. substd. divalent linking chain of 1-10 atoms selected from C. N, O and S; Q = organic gp. contg. a basic radical.

USE - (I) are glycoprotein IIb/IIIa antagonists which block the GP IIb/IIIa fibrinogen receptor, inhibit fibrinogen binding and platelet aggregation and prevent thrombus formation and thrombosis. They are useful for treatment or prophylaxis of thrombogenic diseases. The use of (I) is claimed for treating atherosclerosis, arteriosclerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischaemic attacks or strokes, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis following angioplasty, carotid endarterectomy and ana osmosis of vascular grafts. (I) may also be used for: preventing platelet aggregation, embolisation or consumption in extracorporeal circulation (e.g. for improving renal dialysis, cardiopulmonary bypasses, haemoperfusions and plasmapheresis) or associated with intravascular devices (e.g. intraaortic balloon pumps, ventricular assist devices or arterial catheters; treating or preventing venous thrombosis (e.g. deep venous thrombosis, IVC, renal or portal vein thrombosis or pulmonary venous thrombosis); treating disorders involving platelet consumption (e.g. thrombocytopoenic purpura); or inhibiting platelet aggregation in non-therapeutic applications (e.g. platelet or whole blood storage). (I) are administered orally, **parenterally**, topically or rectally. Daily dose is 0.01-10000 (pref. 1-300) mg.

Dwg.0/0

ABEQ US 5618843 A UPAB: 970516

A novel compound is selected from the group represented by formulae I and II, or mixtures thereof.

Dwg.0/0